CompletedNot Applicable

Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.

France233 participantsStarted 2017-01-10

Plain-language summary

The pre-eclampsia is a frequent pathology, concerning approximately 5 % of the pregnancies.The pre-eclampsia can evolve into severe maternal and\\or foetal complications and is a major cause of mortality. The purpose of the study will to estimate the relevance of the serum markers sFlt1 and PlGF to predict the arisen of severe complications at these patients, what would allow to decrease the materno-fœtale morbi-mortality due to the pathology.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * pregnant woman with a diagnosis of placental vascular disease (gestational hypertension, preeclampsia, IUGR) Exclusion Criteria: * patient who refuses the obstetric follow-up

What they're measuring

Arisen of a maternal and/or fetal severe complication

Timeframe: during the pregnancy from 24 weeks of gestation until delivery

Trial details

NCT IDNCT03455387

SponsorCentre Hospitalier Metropole Savoie

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-12-20

View on ClinicalTrials.gov More Pre-Eclampsia trials